SILO Silo Pharma, Inc.

CIK 0001514183 25 ready 8-Ks latest June 3, 2026, 5:00 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 25

Latest filing June 3, 2026, 5:00 PM ET

Top materiality 0.90

Event mix other_material ×19 · regulatory ×3 · m_and_a ×2

Sentiment 4 pos · 3 neg · 18 neu

SHENANIGAN SCORE 4 / 7 dying AND reaching see the board

Recent 8-K filings for SILO

Highest-materiality recent filing

Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15

July 8, 2024, 7:59 PM ET other material materiality 0.90 positive item 1.01 item 8.01 item 9.01

License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Agreement includes initial and annual fees from low to mid five figures, milestone payments, and royalties on net revenues.

Read filing →

June 3, 2026, 5:00 PM ET other material materiality 0.70 negative item 3.03 item 5.03 item 8.01 item 9.01

Silo Pharma announces 1-for-15 reverse stock split effective June 2, 2026

Every 15 shares of common stock combined into 1 share; par value unchanged at $0.0001.
February 23, 2026, 6:59 PM ET other material materiality 0.85 positive item 3.02 item 8.01 item 9.01

Silo Pharma authorizes $1M buyback; pays IR consultant 848k shares

Board approved stock repurchase program up to $1 million of common stock.
December 29, 2025, 6:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices

Silo Pharma receives Nasdaq extension until June 22, 2026 to regain minimum bid price compliance

Company failed to meet $1.00 minimum bid price requirement by initial Dec. 24, 2025 deadline.
October 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07 item 9.01

Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M

Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.
August 5, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Silo Pharma launches crypto treasury strategy; appoints Corwin Yu to advisory board

Board established Crypto Advisory Board (up to 3 members); appointed Corwin Yu as first member.
July 3, 2025, 7:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices

Silo Pharma receives Nasdaq deficiency notice for bid price below $1.00

Nasdaq notified Silo of non-compliance with minimum bid price rule after 30 consecutive business days below $1.00, from May 14 to June 26, 2025.
May 16, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Silo Pharma closes $2M public offering of common stock and warrants

Offered 3,333,338 shares (or pre-funded warrants) plus Series A-1 and A-2 warrants for up to 3,333,338 shares each.
January 2, 2025, 6:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Silo Pharma issues shareholder letter: SPC-15 IND expected 2025, SP-26 animal studies in early 2025

IND submission for SPC-15 intranasal PTSD treatment expected in 2025; Phase 1 trial to follow upon FDA approval.
July 8, 2024, 7:59 PM ET other material materiality 0.90 positive item 1.01 item 8.01 item 9.01

Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15

License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
June 4, 2024, 7:59 PM ET regulatory materiality 0.60 neutral item 8.01 item 9.01

Silo Pharma submits pre-IND to FDA for SPC-15 intranasal PTSD treatment

SPC-15 is an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.55 · Most common event other_material

4 positive 3 negative 18 neutral

source · SILO on sec.gov